Panzyga
NDC 68982-820
View dosage, usage, ingredients, routes, and UNII mappings.
Product Information
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Panzyga is a BLA-approved product labeled by Octapharma Usa Inc. This medication is used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. It is supplied as a product. This product entry covers the primary NDC 68982-820 and 6 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
68982-820
Proprietary Name:
Panzyga
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
68982
Product Label ID:
HCPCS Code:
J1576
- INJECTION, IMMUNE GLOBULIN (PANZYGA), INTRAVENOUS, NON-LYOPHILIZED (E.G., LIQUID), 500 MG
FDA Application Number: [6]
BLA125587
Marketing Category: [8]
BLA - A product marketed under an approved Biologic License Application.
Marketing Timeline
Start Marketing Date: [9]
11-12-2018
Listing Expiration Date: [11]
12-31-2022
Exclude Flag: [12]
I
Code Structure Chart
Product Details
What is NDC 68982-820?
The NDC code 68982-820 is assigned by the FDA to the product Panzyga. This pharmaceutical product is labeled by Octapharma Usa Inc and is currently categorized as listed product. In terms of distribution, this product is available in 6 different package configurations. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
This medication is used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. This medication is made from healthy human blood that has a high level of certain defensive substances (antibodies), which help fight infections. It is also used to increase the blood count (platelets) in persons with a certain blood disorder (idiopathic thrombocytopenia purpura-ITP). Platelets are needed to stop bleeding and form blood clots. Some immune globulin products may also be used to treat a certain type of muscle weakness problem (multifocal motor neuropathy) or a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). Some products may also be used to prevent certain blood vessel disorders in people with Kawasaki syndrome.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- HUMAN IMMUNOGLOBULIN G (UNII: 66Y330CJHS)
- HUMAN IMMUNOGLOBULIN G (UNII: 66Y330CJHS) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 2102435 - immune globulin intravenous (human) - ifas 10 % in 10 ML Injection
- RxCUI: 2102435 - 10 ML immune globulin intravenous (human) - ifas 100 MG/ML Injection
- RxCUI: 2102435 - immune globulin intravenous (human) - ifas 10 % per 10 ML Injection
- RxCUI: 2102440 - panzyga 10 % in 10 ML Injection
- RxCUI: 2102440 - 10 ML immune globulin intravenous (human) - ifas 100 MG/ML Injection [Panzyga]
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".
